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Abstract 
 
Background: amblyopia is a major cause of visual impairment in children. Our aim is to compare patching and 
atropine penalization for treatment of moderate amblyopia in 4-10 years old children. 
 
Methods: During 2004-2007, in a randomized clinical trial, 120 patients aged 4-10 years old with moderate 
amblyopia in the range of 20/40 -20/100 were enrolled. Subjects randomized either to patch therapy or twice 
weekly atropine penalization in equal groups and were followed for 2 years. The success rate was defined as 
increment of 2 or more lines of visual acuity or final visual acuity of 20/25 or better. 
 
Results: The visual acuity in amblyopic eye improved from base line to a mean of 3.8 lines in patching group 
and mean of 3.7 lines in atropine group at the end of follow up. The average visual acuity in both groups was 0.5 
Log MAR acuity that increased to 0.18 in patching group and 0.2 in atropine group. 
 
Conclusion: Twice weekly atropine penalization could improve visual acuity of a magnitude like to improvement 
provided by patching in treatment of moderate amblyopia in patients aged 4-10 years. 
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Introduction 
 
Amblyopia is the most common cause of monocular 
visual loss in children.
1
 Patch and atropine penaliza-
tion of the sound eye has been the mainstay of the 
sound eye.
2-4 Simons et al.,
5 reported that atropine 
therapy (one drop in a week) was a successful treat-
ment as daily therapy. A pediatric eye disease inves-
tigation group
6 reported that 2 hours patching im-
proved the moderate to severe amblyopia in 3-7 years 
children. Pediatric Eye Disease Investigation Group 
reported that daily atropine or patching has similar 
improvement of moderate amblyopia.
2-4 We conduct-
ed a randomized clinical trial to compare the success 
rate of atropine administration twice a week with 2 
hours patching for treatment of moderate amblyopia. 
 
 
Materials and Methods  
 
This prospective randomized clinical trial was under-
taken in 120 subjects. Patients with the following cri-
teria were enrolled. 1. Age of 4-10 years, 2. Visual 
acuity (VA) in amblyopic eye between 20/40 and 
20/100, 3. Difference of visual acuity between eyes of 
equal or more than 3 Log MAR, 4. Difference in re-
fractive error between eyes of equal or more than 1 
diopter for hyperopia and 1.5 diopter for astigmatism, 
5. Wearing of optical correction for at least 4 weeks 
and 6. At least 2 years follow-up. 
Informed consent was obtained from the subjects 
before treatment. Randomization was done on the 
patients records, the even number assigned to 3 hours 
patch therapy and odd numbers for those undergone 
penalization with 0.5% atropine twice a week. The 
number of subjects in each group was 60 patients. 
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Cycloplegic refraction was done with 0.5% cyclopen-
tolate. Suitable glass was prescribed and after one 
month of wearing of glass, VA was checked with E 
chart (nidek projector) at initiation of treatment and at 
each visit.  
Successful treatment was defined as 2 or more lines 
of improvement in VA or VA of 20/25 or better in am-
blyopic eye. Then final mean of VA or amblyopic eye 
and rate of successful treatment of both groups were 
evaluated with SPSS software (Version 16, Chicago, 
IL, USA). This study was approved by Ethics Commit-
tee of Guilan University of Medical Sciences. 
 
 
Results 
 
Between January 2004 and January 2007, 120 sub-
jects entered this study. Sixty patients were assigned 
to patching group and the same assigned to penaliza-
tion group. About 45% of patients were female and 
the remainders were male. The mean VA in patching 
and penalization groups at initiation of treatment were 
0.46 and 0.45 Log MAR respectively. The pre-
treatment data of patients were summarized in Table 1. 
Sixty subjects were enrolled including patching 
group, so that in patients with two lines acuity differ-
ence between eyes, 2 hours patch therapy was per-
formed and in subjects with three or more lines dif-
ference, 3 hours patch therapy was started. The suc-
cessful rate of treatment was about 76%. About 50% 
of patients achieved VA of 20/25 or more at the end 
of follow-up. The frequency of patients achieved spe-
cial level of VA in both groups that was summarized 
in Table 2. The mean increment of visual from base 
line was 3.6 lines. About 35% of achieved stereo acu-
ity of 400 second of arc at the end of follow-up. The 
VA and improvement at the end of two years were 
summarized in Table 2. 
Sixty subjects received penalization with 0.5% at-
ropine twice a week. During improvement of the VA, 
the penalization dose decreased to one drop weekly. 
The successful rate of treatment was about 74%. 
About 50% of patients achieved VA of 20/25 or more 
at the end of follow-up. About 30% of patients 
achieved stereoacuity of 400 second of arc at the end 
of follow-up.  
Table 1: Pre treatment patients’ data 
  Total patients Patching group Penalization group
Male 
Sex 
Female 
55% 
 
45% 
54% 
 
46% 
56% 
 
46% 
4-<6 
Age             6-<8 
8-10 
50 
50    
20 
26 
24 
10 
24 
26 
10 
VA in amblyopia 
Snellen      Log MAR 
20/100        0.7 
20/80          0.6 
20/60          0.48 
20/50          0.4 
20/40          0.3   
Mean Log MAR 
 
 
15 
17   
31 
25 
32       
0.45  
          
            
8 
8 
15 
13 
16 
0.45 
             
            
7 
9 
16 
12 
16 
0.45 
VA  in sound  eye 
Snellen       Log MAR 
20/20          0 
20/25          0.1 
20/30          0.2 
20/40          0.3 
        
        
80 
20 
15 
5 
        
             
41 
9 
7 
3  
 
               
39 
11 
8 
2 
Amount of anisometropia 
1-<2 
2-<3 
3-<4 
4-<5 
 
 
60 
30 
20 
10   
            
 
31 
15 
9 
5 
      
        
29  
15 
11 
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Among 120 patients, VA test at the end of treatment 
in both groups was summarized. The successful rate of 
treatment was about 75%. About 50% of patients 
achieved VA of 20/25 or more at the end of follow-up. 
The frequency of patients achieved the special level of 
VA in both groups was summarized in Table 2. 
 
 
Discussion 
 
We compared the effects of patching and atropine 
penalization for treatment of moderate amblyopia in 
120 subjects aged 4-10 years in a randomized clinical 
trial. The mean VA at the end of treatment was 0.18 
Log MAR or 20/30 in both groups. The VA in am-
blyopic eye increased from base line to a mean of 3.8 
lines in patching and 3.6 lines in penalization groups. 
There was no statistically significant difference be-
tween both groups. The successful rate of treatment in 
penalization and patching groups were 74% and 76% 
respectively. There was no significant difference be-
tween the 2 groups in mean of VA or line of im-
provement. About 35% of patching group and 30% of 
atropine group achieved stereoacuity of 400 second of 
arc at the end of follow-up. Pediatric Eye Disease 
Investigation Group
3 in their randomized trial of atro-
pine VS patching of moderate amblyopia reported 
that 51% of patching group and 49% of atropine 
group achieved VA of 20/25 or better. Also at the end 
of follow-up, VA improved from base line to a mean 
of 3.7 lines in the patching and 3.6 lines in atropine 
group. PEDIG
7 in a randomized trial of atropine VS 
patching for treatment of amblyopia for follow-up at 
age of 10 years showed that patching and penalization 
with atropine resulted in a comparable improvement 
in VA of amblyopic eye. Their reports were like our 
results. PEDIG
2 in another study showed that visual 
acuity improved in both groups from base line 3.16 
lines in patch group and 2.84 lines in atropine group. 
The success rates of treatment were 79% in patching 
group and 74% in atropine group. Simons
5 reported 
that atropine treatment may produce better binocular 
function than patching treatment. 
Our study showed that patching treatment and pe-
nalization with atropine had the same therapeutic ef-
fect for treatment of moderate amblyopia in patients 
of 4-10 years old. 
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